<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: The CD44, a cell surface <z:chebi fb="0" ids="37396">proteoglycan</z:chebi>, participates in a variety of function including <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> dissemination and <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>However, there are no available data on the prognostic significance of CD44 expression of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> tissue correlated with serum sCD44 level in childhood <z:hpo ids='HP_0001909'>leukemias</z:hpo> and <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Serum levels and leukemic cell <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> tissue expression of CD44 were detected in 54 children with <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> and malignant <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Serum samples were obtained from <z:hpo ids='HP_0000001'>all</z:hpo> patients before treatment and during remission </plain></SENT>
<SENT sid="4" pm="."><plain>Twelve age-matched healthy children were included as a control group </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: The serum CD44 levels were significantly higher in patients with <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">Hodgkin's disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>), non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (NHL), Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) and <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> (ALL) than those in the control group </plain></SENT>
<SENT sid="6" pm="."><plain>The median values were 1627.0, 1336.0, 1318.5, 1730.4, 902.7 ng/mL, respectively, and P&lt;0.001, P&lt;0.01, P&lt;0.01, P&lt;0.05 in comparisons, respectively </plain></SENT>
<SENT sid="7" pm="."><plain>However, there was no significant difference between <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) and the control group (median values: 900.3 and 902.7 ng/mL, respectively, P&gt;0.05) </plain></SENT>
<SENT sid="8" pm="."><plain>Serum sCD44 levels significantly declined in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>, NHL and ALL patients who were in complete remission (median values: 684.0, 573.8 and 1101.1 ng/mL, respectively, P&lt;0.05 in each comparison) </plain></SENT>
<SENT sid="9" pm="."><plain>Patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e> had higher levels of serum sCD44 and correlated well with higher erythrocyte sedimentation rate (ESR), B-symptoms and advanced-stage disease (P&lt;0.05, P&lt;0.05 and P&lt;0.01, respectively) </plain></SENT>
<SENT sid="10" pm="."><plain>Expression of CD44 was significantly high in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e> and NHL who were in advanced stages of disease </plain></SENT>
<SENT sid="11" pm="."><plain>High serum CD44 level was also associated with high <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> tissue expression of CD44 in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> </plain></SENT>
<SENT sid="12" pm="."><plain>In addition, patients with higher levels of serum sCD44, had a poorer outcome and survival than those with lower sCD44 levels in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e> and NHL groups </plain></SENT>
<SENT sid="13" pm="."><plain>CONCLUSIONS: A high serum sCD44 level and/or <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> tissue expression at diagnosis is associated with poor prognostic criteria and/or unfavorable outcome in childhood <z:hpo ids='HP_0001909'>leukemias</z:hpo> and <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
</text></document>